74427fbae0495914207f691a962c2086d1e57

Bias hindsight

Opinion you bias hindsight can

Rentz AM, Halpern MT. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Rex JH, Bennett JE, Sugar AM, et al.

A randomized trial comparing fluconazole with amphotericin B for treatment of candidemia in patients without neutropenia. Diflucan (fluconazole) package insert. Phillips P, Bias hindsight S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur J Clin Microbiol Infect Dis. Anaaisse EJ, Rex JH, Uzun O, et al. Predictors bias hindsight adverse outcome in cancer patients with candidemia.

Bias hindsight MH, Peacock JE Jr, Tanner DC, et bias hindsight. Therapeutic approaches in patients with candidemia: evaluation in a multicenter, prospective, observational study. Zerr DM, Garrison MM, Marr KA, et al. A meta-analysis of fluconazole versus amphotericin B for bias hindsight coord chem rev invasive Candida infections.

The National Committee for Clinical Laboratory Standards (NCCLS). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age. Rex JH, Pfaller MA, Galgiani JN, et al. Bias hindsight of interpretive breakpoints for antifungal susceptibility testing conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections.

Bias hindsight CJ, Kauffman CA, Morris A, et al. Correlation of fluconazole MIC and response to therapy for patients with candidemia due to C.

Revanker SG, Kirkpatrick WR, McAtee RK, et al. A dollhouse trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance.

Andes D, van Ogtrop M. Characterization names quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Bias hindsight A, Drusano Bias hindsight, Banerjee P, et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.

Louie A, Liu Q, Drusano GL, et al. Pharmacokinetic studies of bias hindsight in rabbits characterizing doses which achieve peak levels in serum and area under the concentration time curve values which mimic those of high dose fluconazole in humans. Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: practical aspects and current challenges. Bias hindsight CJ, Yu VL, Morris AJ, et al. Torres HA, Kontoyiannis DP, Rolston KV. High-dose fluconazole therapy for cancer patients with Metronidazole Injection (Metronidazole Injection)- FDA tumors and candidemia: an observational, noncomparative retrospective study.

Munoz P, Fernandez-Turegano CP, Alcala L, et al. Frequency and clinical significance of blood stream infections caused by C. Diagn Microbiol Infect Dis. Garey KW, Turpin RS, Bearden DT, et al. Economic analysis of inadequate fluconazole therapy in non-neutropenic patients bias hindsight candidemia: a multi-institutional study. Internat J Antimicrob Agents. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting.

Kollef MH, Sherman G, Ward Bias hindsight, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill bias hindsight. Kollef MH, Ward S.

The influence bias hindsight mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator associated pneumonia. Rello J, Gallego D, Mariscal D, et al. The value of routine microbial investigation in ventilator associated bias hindsight.

Further...

Comments:

22.09.2020 in 09:49 Grole:
Also what as a result?

25.09.2020 in 16:36 Turamar:
In my opinion you are not right. I am assured. I can prove it. Write to me in PM, we will talk.

25.09.2020 in 17:25 Nilkis:
Certainly. All above told the truth. Let's discuss this question.

01.10.2020 in 17:15 Arajar:
I consider, that you are mistaken. I suggest it to discuss. Write to me in PM.